|
1
|
Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss
J, Szendroi M, Csoka M and Kovacs G: Good prognosis of localized
osteosarcoma in young patients treated with limb-salvage surgery
and chemotherapy. Pediatr Blood Cancer. 57:415–422. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jaffe N: Osteosarcoma: Review of the past,
impact on the future. The American experience. Cancer Treat Res.
152:239–262. 2009. View Article : Google Scholar
|
|
3
|
van Maldegem AM, Bhosale A, Gelderblom HJ,
Hogendoorn PC and Hassan AB: Comprehensive analysis of published
phase I/II clinical trials between 1990–2010 in osteosarcoma and
Ewing sarcoma confirms limited outcomes and need for translational
investment. Clin Sarcoma Res. 2:52012. View Article : Google Scholar
|
|
4
|
Chan DC: Mitochondria: Dynamic organelles
in disease, aging, and development. Cell. 125:1241–1252. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Neuzil J, Dong LF, Rohlena J, Truksa J and
Ralph SJ: Classification of mitocans, anti-cancer drugs acting on
mitochondria. Mitochondrion. 13:199–208. 2013. View Article : Google Scholar
|
|
6
|
Yamada S, Nomoto S, Fujii T, Kaneko T,
Takeda S, Inoue S, Kanazumi N and Nakao A: Correlation between copy
number of mitochondrial DNA and clinico-pathologic parameters of
hepatocellular carcinoma. Eur J Surg Oncol. 32:303–307. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu M, Zhou Y, Shi Y, Ning L, Yang Y, Wei
X, Zhang N, Hao X and Niu R: Reduced mitochondrial DNA copy number
is correlated with tumor progression and prognosis in Chinese
breast cancer patients. IUBMB Life. 59:450–457. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu CW, Yin PH, Hung WY, Li AF, Li SH, Chi
CW, Wei YH and Lee HC: Mitochondrial DNA mutations and
mitochondrial DNA depletion in gastric cancer. Genes Chromosomes
Cancer. 44:19–28. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee HC, Li SH, Lin JC, Wu CC, Yeh DC and
Wei YH: Somatic mutations in the D-loop and decrease in the copy
number of mitochondrial DNA in human hepatocellular carcinoma.
Mutat Res. 547:71–78. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xing J, Chen M, Wood CG, Lin J, Spitz MR,
Ma J, Amos CI, Shields PG, Benowitz NL, Gu J, et al: Mitochondrial
DNA content: Its genetic heritability and association with renal
cell carcinoma. J Natl Cancer Inst. 100:1104–1112. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tseng LM, Yin PH, Chi CW, Hsu CY, Wu CW,
Lee LM, Wei YH and Lee HC: Mitochondrial DNA mutations and
mitochondrial DNA depletion in breast cancer. Genes Chromosomes
Cancer. 45:629–638. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim MM, Clinger JD, Masayesva BG, Ha PK,
Zahurak ML, Westra WH and Califano JA: Mitochondrial DNA quantity
increases with histopathologic grade in premalignant and malignant
head and neck lesions. Clin Cancer Res. 10:8512–8515. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin CS, Chang SC, Wang LS, Chou TY, Hsu
WH, Wu YC and Wei YH: The role of mitochondrial DNA alterations in
esophageal squamous cell carcinomas. J Thorac Cardiovasc Surg.
139:189–197.e4. 2010. View Article : Google Scholar
|
|
14
|
Wang Y, Liu VW, Xue WC, Cheung AN and Ngan
HY: Association of decreased mitochondrial DNA content with ovarian
cancer progression. Br J Cancer. 95:1087–1091. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Onishi Y, Ueha T, Kawamoto T, Hara H, Toda
M, Harada R, Minoda M, Kurosaka M and Akisue T: Regulation of
mitochondrial proliferation by PGC-1α induces cellular apoptosis in
musculoskeletal malignancies. Sci Rep. 4:39162014. View Article : Google Scholar
|
|
16
|
Ekstrand MI, Falkenberg M, Rantanen A,
Park CB, Gaspari M, Hultenby K, Rustin P, Gustafsson CM and Larsson
NG: Mitochondrial transcription factor A regulates mtDNA copy
number in mammals. Hum Mol Genet. 13:935–944. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Corton JM, Gillespie JG, Hawley SA and
Hardie DG: 5-Aminoimidazole-4-carboxamide ribonucleoside. A
specific method for activating AMP-activated protein kinase in
intact cells? Eur J Biochem. 229:558–565. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Swinnen JV, Beckers A, Brusselmans K,
Organe S, Segers J, Timmermans L, Vanderhoydonc F, Deboel L, Derua
R, Waelkens E, et al: Mimicry of a cellular low energy status
blocks tumor cell anabolism and suppresses the malignant phenotype.
Cancer Res. 65:2441–2448. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jäger S, Handschin C, St-Pierre J and
Spiegelman BM: AMP-activated protein kinase (AMPK) action in
skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl
Acad Sci USA. 104:12017–12022. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Narkar VA, Downes M, Yu RT, Embler E, Wang
YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, et al:
AMPK and PPARdelta agonists are exercise mimetics. Cell.
134:405–415. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Okada Y, Akisue T, Hara H, Kishimoto K,
Kawamoto T, Imabori M, Kishimoto S, Fukase N, Onishi Y and Kurosaka
M: The effect of bevacizumab on tumour growth of malignant fibrous
histiocytoma in an animal model. Anticancer Res. 30:3391–3395.
2010.PubMed/NCBI
|
|
22
|
Yu M, Wan Y and Zou Q: Decreased copy
number of mitochondrial DNA in Ewing's sarcoma. Clin Chim Acta.
411:679–683. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Friebele JC, Peck J, Pan X, Abdel-Rasoul M
and Mayerson JL: Osteosarcoma: A Meta-Analysis and Review of the
Literature. Am J Orthop (Belle Mead NJ). 44:547–553. 2015.
|
|
24
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sanli T, Rashid A, Liu C, Harding S,
Bristow RG, Cutz JC, Singh G, Wright J and Tsakiridis T: Ionizing
radiation activates AMP-activated kinase (AMPK): A target for
radiosensitization of human cancer cells. Int J Radiat Oncol Biol
Phys. 78:221–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gwinn DM, Shackelford DB, Egan DF,
Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK
phosphorylation of raptor mediates a metabolic checkpoint. Mol
Cell. 30:214–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shackelford DB and Shaw RJ: The LKB1-AMPK
pathway: Metabolism and growth control in tumour suppression. Nat
Rev Cancer. 9:563–575. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mihaylova MM and Shaw RJ: The AMPK
signalling pathway coordinates cell growth, autophagy and
metabolism. Nat Cell Biol. 13:1016–1023. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng J, Huang T, Li Y, Guo Y, Zhu Y, Wang
Q, Tan X, Chen W, Zhang Y, Cheng W, et al: AMP-activated protein
kinase suppresses the in vitro and in vivo proliferation of
hepatocellular carcinoma. PLoS One. 9:e932562014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo D, Hildebrandt IJ, Prins RM, Soto H,
Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, et
al: The AMPK agonist AICAR inhibits the growth of
EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc
Natl Acad Sci USA. 106:12932–12937. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sauer H, Engel S, Milosevic N, Sharifpanah
F and Wartenberg M: Activation of AMP-kinase by AICAR induces
apoptosis of DU-145 prostate cancer cells through generation of
reactive oxygen species and activation of c-Jun N-terminal kinase.
Int J Oncol. 40:501–508. 2012.
|
|
32
|
Su RY, Chao Y, Chen TY, Huang DY and Lin
WW: 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL-and
TNF{alpha}-induced cytotoxicity in colon cancer cells through
AMP-activated protein kinase signaling. Mol Cancer Ther.
6:1562–1571. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Woodard J and Platanias LC: AMP-activated
kinase (AMPK)-generated signals in malignant melanoma cell growth
and survival. Biochem Biophys Res Commun. 398:135–139. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Van Den Neste E, Cazin B, Janssens A,
González-Barca E, Terol MJ, Levy V, Pérez de Oteyza J, Zachee P,
Saunders A, de Frias M, et al: Acadesine for patients with
relapsed/refractory chronic lymphocytic leukemia (CLL): A
multicenter phase I/II study. Cancer Chemother Pharmacol.
71:581–591. 2013. View Article : Google Scholar :
|
|
35
|
Aronson S: An initial multicenter,
randomized controlled trial on the safety and efficacy of acadesine
in patients undergoing coronary artery bypass graft surgery. Anesth
Analg. 79:1021–1022. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Newman MF, Ferguson TB, White JA, Ambrosio
G, Koglin J, Nussmeier NA, Pearl RG, Pitt B, Wechsler AS, Weisel
RD, et al: RED-CABG Steering Committee and Investigators: Effect of
adenosine-regulating agent acadesine on morbidity and mortality
associated with coronary artery bypass grafting: The RED-CABG
randomized controlled trial. JAMA. 308:157–164. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fu X, Wan S, Lyu YL, Liu LF and Qi H:
Etoposide induces ATM-dependent mitochondrial biogenesis through
AMPK activation. PLoS One. 3:e20092008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hawley SA, Ross FA, Chevtzoff C, Green KA,
Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, Evans AM, et
al: Use of cells expressing gamma subunit variants to identify
diverse mechanisms of AMPK activation. Cell Metab. 11:554–565.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
El-Mir MY, Nogueira V, Fontaine E, Avéret
N, Rigoulet M and Leverve X: Dimethylbiguanide inhibits cell
respiration via an indirect effect targeted on the respiratory
chain complex I. J Biol Chem. 275:223–228. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Owen MR, Doran E and Halestrap AP:
Evidence that metformin exerts its anti-diabetic effects through
inhibition of complex 1 of the mitochondrial respiratory chain.
Biochem J. 348:607–614. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brunmair B, Staniek K, Gras F, Scharf N,
Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhäusl W, et al:
Thiazolidinediones, like metformin, inhibit respiratory complex I:
A common mechanism contributing to their anti-diabetic actions?
Diabetes. 53:1052–1059. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Turner N, Li JY, Gosby A, To SW, Cheng Z,
Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, James DE, et al:
Berberine and its more biologically available derivative,
dihydroberberine, inhibit mitochondrial respiratory complex I: A
mechanism for the action of berberine to activate AMP-activated
protein kinase and improve insulin action. Diabetes. 57:1414–1418.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jose C, Hébert-Chatelain E, Bellance N,
Larendra A, Su M, Nouette-Gaulain K and Rossignol R: AICAR inhibits
cancer cell growth and triggers cell-type distinct effects on
OXPHOS biogenesis, oxidative stress and Akt activation. Biochim
Biophys Acta. 1807:707–718. 2011. View Article : Google Scholar : PubMed/NCBI
|
